Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar 24:125:158-164.
doi: 10.1016/j.ces.2014.06.042.

Smart Nanoparticles for Drug Delivery: Boundaries and Opportunities

Affiliations

Smart Nanoparticles for Drug Delivery: Boundaries and Opportunities

Byung Kook Lee et al. Chem Eng Sci. .

Abstract

Various pharmaceutical particles have been used in developing different drug delivery systems ranging from traditional tablets to state-of-the-art nanoparticle formulations. Nanoparticle formulations are unique in that the small size with huge surface area sometimes provides unique properties that larger particles and bulk materials do not have. Nanoparticle formulations have been used in improving the bioavailability of various drugs, in particular, poorly soluble drugs. Nanoparticle drug delivery systems have found their unique applications in targeted drug delivery to tumors. While nanoparticle formulations have been successful in small animal xenograft models, their translation to clinical applications has been very rare. Developing nanoparticle systems designed for targeted drug delivery, e.g., treating tumors in humans, requires clear understanding of the uniqueness of nanoparticles, as well as limitations and causes of failures in clinical applications. It also requires designing novel smart nanoparticle delivery systems that can increase the drug bioavailability and at the same time reduce the drug's side effects.

Keywords: Liposome; Nanoparticle; Polymer micelle; Poorly soluble drug; Targeted drug delivery; nanocrystal.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Relative sizes of various pharmaceutical particles ranging from nanoparticles to tablets.
Fig. 2
Fig. 2
Examples of nanoparticles and their relative sizes.
Fig. 3
Fig. 3
Ideal sequence of targeted drug delivery to a tumor. (Adapted from Reference [43]).

References

    1. Dokoumetzidis A, Macheras P. A century of dissolution research: From Noyes and Whitney to the Biopharmaceutics Classification System. Int. J. Pharm. 2006;321:1–11. - PubMed
    1. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: Therapeutic applications and developments. Clinical Pharmacology & Therapeutics. 2008;83:761–769. - PubMed
    1. Cho K, Wang Xu, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 2008;14:1310–1316. - PubMed
    1. Irvine DJ. Drug delivery: One nanoparticle, one kill. Nat Mater. 2011;10:342–343. - PMC - PubMed
    1. Florence AT. “Targeting” nanoparticles: The constraints of physical laws and physical barriers. J. Control. Release. 2012;164:115–124. - PubMed